Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
Last trade$4.75
Day change+$0.995 (+26.53%)
Day range$3.66 – $4.93
Volume1,459,541
Market cap$56M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$56.11M
Price / earnings
—
Price / book
2.7×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.39×
Profitability
Earnings per share
-$1.95
Return on assets
-103.68%
Return on equity
-140.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.16×
Current ratio
3.9×
Quick ratio
3.9×
Cash ratio
3.58×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$24.16M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CING, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$4.58M
$3.93M
$5.74M
$3.58M
$3.15M
$1.95M
$1.48M
$1.88M
Research and development
$2.91M
$1.49M
$2.18M
$2M
$2.85M
$2.7M
$2.22M
$4.33M
Total operating expenses
$7.49M
$5.41M
$7.92M
$5.59M
$6M
$4.65M
$3.71M
$6.21M
Operating income
-$7.49M
-$5.41M
-$7.92M
-$5.59M
-$6M
-$4.65M
-$3.71M
-$6.21M
Interest expense
-$171.06K
-$141.28K
-$536.84K
$0
-$573.06K
-$138.76K
-$96.66K
$0
Income before taxes
-$7.73M
-$5.87M
-$9.31M
-$6.27M
-$7.34M
-$4.98M
-$3.85M
-$6.23M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$7.73M
-$5.87M
-$9.31M
-$6.27M
-$7.34M
-$4.98M
-$3.85M
-$6.23M
Net income attributable to common shareholders
-$7.73M
-$5.87M
-$9.31M
-$6.27M
-$7.34M
-$4.98M
-$3.85M
-$6.23M
EBITDA
-$7.44M
-$5.32M
-$7.8M
-$5.46M
-$5.89M
-$4.5M
-$3.54M
-$6.05M
Basic earnings per share
-$0.53
-$0.45
-$0.95
-$0.93
-$1.35
-$1.14
-$1.06
-$1.87
Diluted earnings per share
-$0.53
-$0.45
-$0.95
-$0.93
-$1.35
-$1.14
-$1.06
-$1.87
Recent news
Company coverage with links to the original publishers.
Cingulate Inc. reported Q3 2026 financial results with cash of $23.2 million and announced substantial completion of manufacturing work to address FDA CMC information requests for its lead ADHD drug CTx-1301. The company expects to resubmit the NDA between December 2026 and January 2027. The FDA's Complete Response Letter did not raise safety or efficacy concerns. Net loss for nine months ended September 30, 2026 was $22.9 million, with increased SG&A expenses driven by commercial readiness build-out.
Cingulate Inc. placed CEO Shane J. Schaffer on administrative leave due to unrelated legal matters. Jennifer Callahan was appointed interim CEO, retaining her CFO role, while board member Jay Roberts became Executive Chairman to ensure business continuity.
Allarity Therapeutics announced the appointment of Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings nearly two decades of executive leadership experience in healthcare and biotech sectors, and will support the company's clinical development of stenoparib, a cancer treatment drug.
Cingulate Inc. reported positive results for its lead ADHD asset CTx-1301, including successful completion of Phase 3 trials and plans to submit a New Drug Application in mid-2025. The company also strengthened its balance sheet through various financing activities.
Cingulate Inc. has adjourned its Special Meeting of Stockholders to provide additional time for stockholders to vote on all proposals. The company's Board of Directors continues to believe that the proposals are in the best interests of the stockholders.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.